SCHEMBL3483693

SCHEMBL3483693

O=C(/C=C/c1ccc(O)cc1)c1ccc(NS(=O)(=O)c2ccccc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 4/20 0.66
HDAC4 P56524 4/20 0.66
HDAC1 Q13547 4/20 0.66
HDAC7 Q8WUI4 4/20 0.66
HDAC2 Q92769 4/20 0.66
HDAC10 Q969S8 4/20 0.66
HDAC11 Q96DB2 4/20 0.66
HDAC8 Q9BY41 4/20 0.66
HDAC6 Q9UBN7 4/20 0.66
HDAC9 Q9UKV0 4/20 0.66
HDAC5 Q9UQL6 4/20 0.66
KMT2A Q03164 3/20 0.62
CYP3A4 P08684 2/20 0.62
HSPD1 P10809 2/20 0.62
HSPE1 P61604 2/20 0.62
F3 P13726 2/20 0.62
MEN1 O00255 2/20 0.62
MAPT P10636 2/20 0.62
PKM P14618 1/20 0.62
NFKB1 P19838 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3483695 1.00 HDAC3 (0.66) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL3483881 0.93 F3 (0.64) HDAC4HDAC1HDAC8KMT2AF3
SCHEMBL3483883 0.93 F3 (0.64) HDAC4HDAC1HDAC8KMT2AF3
SCHEMBL3483861 0.89 P4HB (0.60) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL3483862 0.89 P4HB (0.60) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL25200492 0.88 ESR1 (0.68) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL3483831 0.88 LMNA (0.71) HDAC4HDAC1HDAC8KMT2AMEN1
SCHEMBL3483873 0.88 MAPT (0.60) HDAC3HDAC1HDAC8HDAC6KMT2A
SCHEMBL3484501 0.88 F3 (0.56) HDAC1HDAC8KMT2AF3MEN1
SCHEMBL3484498 0.88 F3 (0.56) HDAC1HDAC8KMT2AF3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2601943-B1 Anti-cancer composition containing chalcone compounds SEOUL NAT UNIV IND FOUNDATION (KR) 2015-07-22 EP claimed
US-20130178533-A1 COMPOSITION FOR DIAGNOSING, TREATING, AND PREVENTING LIVER DISEASE SNU R&DB FOUNDATION (KR) 2013-07-11 US claimed
EP-2601943-A1 Anti-cancer composition containing chalcone compounds Seoul National University Industry Foundation (KR) 2013-06-12 EP claimed
US-20100068730-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) 2010-03-18 US claimed
US-20090252694-A1 Novel Chalcone Derivatives, Pharmaceutically Acceptable Salt, Method for Preparation and Uses Thereof INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSTIY (KR) 2009-10-08 US claimed
EP-2099440-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS Seoul National University Industry Foundation (KR) 2009-09-16 EP claimed
WO-2008069608-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS SEOUL NATIONALUNIVERSITY INDUSTRY FOUNDATION (KR) 2008-06-12 WO claimed
WO-2007114532-A1 NOVEL CHALCONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT, METHOD FOR PREPARATION AND USES THEREOF INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY (KR) 2007-10-11 WO claimed
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
EP-2601943-B1 Anti-cancer composition containing chalcone compounds SEOUL NAT UNIV IND FOUNDATION (KR) 2015-07-22 EP disclosed
US-20090252694-A1 Novel Chalcone Derivatives, Pharmaceutically Acceptable Salt, Method for Preparation and Uses Thereof INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSTIY (KR) 2009-10-08 US disclosed
US-20090252694-A1 Novel Chalcone Derivatives, Pharmaceutically Acceptable Salt, Method for Preparation and Uses Thereof INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSTIY (KR) 2009-10-08 US disclosed
US-20090252694-A1 Novel Chalcone Derivatives, Pharmaceutically Acceptable Salt, Method for Preparation and Uses Thereof INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSTIY (KR) 2009-10-08 US disclosed
EP-2099440-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS Seoul National University Industry Foundation (KR) 2009-09-16 EP disclosed
WO-2008069608-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS SEOUL NATIONALUNIVERSITY INDUSTRY FOUNDATION (KR) 2008-06-12 WO disclosed
WO-2007114532-A1 NOVEL CHALCONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT, METHOD FOR PREPARATION AND USES THEREOF INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY (KR) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090252694-A1 Novel Chalcone Derivatives, Pharmaceutically Acceptable Salt, Method for Preparation and Uses Thereof TYR, CYP21A2, CMA1 HDAC3 1826/4885HDAC4 1581/4885HDAC1 1297/4885
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B HDAC3 1434/4885HDAC4 2063/4885HDAC1 1693/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 HDAC3 346/4885HDAC4 933/4885HDAC1 648/4885
US-20100068730-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS TM9SF4, TM9SF2, TM9SF3 HDAC3 3465/4885HDAC4 924/4885HDAC1 4041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.